Morbid obesity presents a significant health risk and impacts the quality of a patient’s life. As minimally invasive, reversible and comfortable medical implant, the HELIOSPHERE® guarantees safe and effective pre-operative treatment for morbid obesity. With two sizes available – 600cc and 720cc you can ensure that you are providing the best individual treatment.
Non-surgical and minimally invasive
Implantation takes around 20 minutes via endoscopy without the need to hospitalise the patient.
Inflated with air
Lightweight and therefore reducing post-implantation nausea, vomiting and discomfort.
Implantation time
6 months
Reinforced & airtight
Protective polymer coating
Simplified implantation
- Easy cover removal system
- Smaller introduction diameter
Simplified Extraction
- Reduced extraction force
- Double skin transparent wall
Information
Gastroplasty surgery to treat obesity is considered only after medically managed diets have failed to achieve long-term weight loss. It is important for the success of treatment that the use of the HELIOSPHERE® 600/720 intragastric balloons is accompanied by medical and dietetic monitoring.
Conditions
The balloon has broad suitability conditions. From overweight patients (BMI ≥ 27) to obese patients who do not meet the criteria for bariatric surgery, to super-obese (BMI ≥ 50) as a gateway to bariatric surgery.Results
Once inflated, the balloon reduces the nominal volume of the stomach. By acting freely in the stomach, HELIOSPHERE® causes a rapid feeling of satiety at meals. The patient eats less and loses weight.
Efficiency
Loss of weight up to as much as 24KG.1
Lowering of surgical risks thanks to the pre-operative reduction in weight. (Flancbaum observes a direct link between surgical risks and the initial Body Mass Index of patient. The reduction in the BMI before by-pass lowers the risk of medical complications or early mortality.3)
1 deflation needle
1 pair of extraction forceps
1 universal connector
Reduction of BMI in 46 patients1
Correlation of surgical risks with initial BMI patients2
Bibliography
1 Erdem, H., et al. (2016). “Effects of Intragastric Balloon on Body Mass Index, Lipid Profile and Blood Glucose Regulation: A Prospective Study.” Dicle Tıp Dergisi 43(1).
1 Palmisano, S., et al. (2016). “Intragastric Balloon Device: Weight Loss and Satisfaction Degree.” Obesity surgery 26(9): 2131-2137.
1 Espinet Coll, E., et al. (2017). “Multicenter study on the safety of bariatric endoscopy.” Rev Esp Enferm Dig 109(5): 350-357.
2 According to the European prospective database (Observatory of HELIOSCOPIE).
3 Factors Affecting Morbidity and Mortality of Roux-en Y Gastric Bypass for Clinically Severe Obesity: An Analysis of 1,000 Consecutive Open Cases by a Single Surgeon. Louis Flancbaum. J Gastrointest Surg (2007) 11:500-507.
Tolerance And Efficacy of an Air-filled Balloon In Non-Morbidly Obese Patients… F. Mion. Obesity Surgery, 2007; 17, 764-769.
Posters from the World Congress of IFSO: Air-Filled Intragastric Balloon (Bag): Italian Multicentric Results. A. Giovanelli (2007).
Heliosphere intragastric Air Balloon: Our Initial Experience in the Dominican Republic. Dk Ramirez. (2006), Intragastric Balloon for Obesity: Comparative Study With 420 Patients: New Generation Air-filled vs Liquid-Filled. C. Hermida. (2006) or from the UEGW: Primary Experience With Air-Filled Intragastric Balloon Compared With Intragastric Balloon Literature Data. H. Claudez (2005) ‘.